Role of ABCA 1 and ABCG 1 in Atherogenesis
暂无分享,去创建一个
[1] G. Franceschini,et al. Functional Lecithin: Cholesterol Acyltransferase Is Not Required for Efficient Atheroprotection in Humans , 2009, Circulation.
[2] Michael J. Pencina,et al. Predicting the 30-Year Risk of Cardiovascular Disease: The Framingham Heart Study , 2009, Circulation.
[3] A. Kontush,et al. Proteomic Analysis of Defined HDL Subpopulations Reveals Particle-Specific Protein Clusters: Relevance to Antioxidative Function , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[4] M. Krieger,et al. Role of the adaptor protein PDZK1 in controlling the HDL receptor SR-BI. , 2009, Current opinion in lipidology.
[5] D. Rader,et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis This work was supported by P01-HL22633 from the NHLBI. Published, JLR Papers in Press, December 8, 2008. , 2009, Journal of Lipid Research.
[6] A. Lichtenstein,et al. Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[7] G. Watts,et al. HDL metabolism in context: looking on the bright side , 2008, Current opinion in lipidology.
[8] Jan Albert Kuivenhoven,et al. The value of HDL genetics , 2008, Current opinion in lipidology.
[9] A. Tall,et al. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. , 2008, Cell metabolism.
[10] M. Caulfield,et al. Effects of torcetrapib in patients at high risk for coronary events , 2008 .
[11] Robert A Hegele,et al. Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency1 Published, JLR Papers in Press, November 8, 2007. , 2008, Journal of Lipid Research.
[12] K. Drosatos,et al. Discrete roles of apoA‐I and apoE in the biogenesis of HDL species: Lessons learned from gene transfer studies in different mouse models , 2008, Annals of medicine.
[13] G. Assmann,et al. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study ‡ , 2007, European journal of clinical investigation.
[14] P. Mitchell,et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial , 2007, The Lancet.
[15] H. Brewer,et al. HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease , 2007, Current cardiology reports.
[16] Y. Matsuzawa,et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.
[17] S. Yamashita,et al. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states Published, JLR Papers in Press, December 20, 2006. , 2007, Journal of Lipid Research.
[18] B. G. Brown,et al. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials , 2006, Current opinion in lipidology.
[19] A. Kontush,et al. Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis , 2006, Pharmacological Reviews.
[20] E. Schaefer,et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction , 2006, Current opinion in lipidology.
[21] C. Furberg,et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). , 2005, The American journal of cardiology.
[22] J. Wittes,et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.
[23] Roberto Marchioli,et al. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .
[24] J Auwerx,et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.
[25] G. Franceschini,et al. High density lipoprotein and coronary heart disease: insights from mutations leading to low high density lipoprotein. , 1997, Current opinion in lipidology.
[26] J. Huttunen,et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. , 1988, JAMA.
[27] H. Mabuchi,et al. Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. , 1985, Atherosclerosis.
[28] K. Rye,et al. High-density lipoproteins, inflammation and oxidative stress. , 2009, Clinical science.
[29] W. Howard,et al. Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis , 2008 .